AbbVie’s skin disease drug reduces lesions in trial, company eyes weight-loss combination

AbbVie skin disorder drug succeeds in late-stage trial, but results miss market expectations

AbbVie's lutikizumab, an experimental therapy for a chronic skin condition, succeeded in a late-stage trial but the results missed market expectations.

AbbVie’s skin disease drug reduces lesions in trial, company eyes weight-loss combination - Regional Media News

By Christy Santhosh Oct 22 (Reuters) - AbbVie said on Thursday its experimental drug significantly reduced inflammatory lumps and abscesses in patients with a chronic skin disease, meeting the main goal of a late-stage study. AbbVie is betting on the drug, lutikizumab, to broaden its [...]

AbbVie’s skin disease drug reduces lesions in trial, company eyes weight-loss combination

By Christy Santhosh Oct 22 (Reuters) - AbbVie said on Thursday its experimental drug significantly reduced inflammatory lumps and abscesses in patients with a chronic skin disease, meeting the main goal ​of a late-stage study. AbbVie is betting on the ...

AbbVie notches Phase 3 win in painful skin condition, FDA filing likely next year

AbbVie unwrapped a Phase 3 success on Thursday for an experimental drug designed to treat a debilitating skin disease. In the trial, AbbVie’s IL-1α and IL-1β inhibitor lutikizumab improved patient response ...